Skip to content

Study on fibrinolytic phenotype and the influence of clinical intervention on prognosis after severe trauma

Study on fibrinolytic phenotype and the influence of clinical intervention on prognosis after severe trauma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076070
Enrollment
Unknown
Registered
2023-09-23
Start date
2023-10-01
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute traumatic coagulation disease

Interventions

research group (Antifibrinolysis was treated with tranexamic acid):None

Sponsors

Taicang First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Patients over 18 years old; (2) Trauma patients have one of the following conditions: SBP 1 or clinical manifestations of shock.

Exclusion criteria

Exclusion criteria: (1) Patients with previous coagulation disorders and long-term oral anticoagulant drugs; (2) Patients with a history of alcoholism, malignant tumor, organ dysfunction, venous thromboembolism, etc.; (3) Patients with DIC and other contraindications in the use of anti-fibrinolytic drugs; (4) ISS 3 hours.

Design outcomes

Primary

MeasureTime frame
TAT,PIC,t-PAIC-1,TM;LY30;24-hour mortality;28-day mortality rate;

Secondary

MeasureTime frame
Reaction time;kinetic time;a angle;maximum amplitude;PT;APTT;D-dmier;fibrinogen;TT;PLT;Mechanical ventilation time;Incidence of venous thromboembolism;Incidence of multiple organ dysfunction;24-hour blood transfusion volume;Length of ICU stay ICU;Total hospitalization days;Total hospital expenses;

Countries

China

Contacts

Public ContactLuping Zhang

Taicang First People's Hospital

zhanglp_861017@163.com+86 158 5029 8061

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026